Galera Therapeutics
Pennsylvania, United States · Healthcare, Health Care · 14 employees
Galera Therapeutics is focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer.
Funding history
- Seed — $2.9M — Jan 2025
- Seed — $2.7M — Jan 2025
- Venture - Series Unknown — $15.0M — Nov 2016
- Venture - Series Unknown — $37.1M — Oct 2015
Recent signals
- May 11, 2026: SEC 8-K (5.03): On May 11, 2026, Galera Therapeutics, Inc. filed a Certificate of Amendment to its Restated Certificate of Incorporation with the Secretary of State of Delaware, increasing the number of authorized shares of common stock from 200 million to 400 million. Additionally, on May 12, 2026, the company provided its stockholders a right to act by written consent through another amendment. Both amendments were approved at the Annual Meeting of Stockholders held on May 8, 2026, indicating a significant change in corporate structure that enhances capital flexibility and shareholder rights. The strategic implications suggest a proactive approach to business expansion and shareholder engagement.
- Apr 14, 2026: Acquired Galera Therapeutics and Obsidian merge to innovate
- Jan 14, 2025: Raised $2.9M in Seed
- Jan 13, 2025: Raised $2.7M in Seed
- Nov 28, 2016: Raised $15.0M in Venture - Series Unknown
- Oct 14, 2015: Raised $37.1M in Venture - Series Unknown
See plans & pricing → Track Galera Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.